{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-21-018381","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2021-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.301309+00:00","generated_at":"2026-06-29T04:30:51.088244+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"X4 Pharmaceuticals promotes Mary DiBiase to COO effective Sep 8, 2021","bullets":["Dr. DiBiase previously SVP of Technical Operations & Quality; now oversees program/alliance mgmt and IT.","Annual base salary $409,500; eligible for annual cash incentive at 40% of base salary target.","Granted 27,000 RSUs vesting equally over three years.","Severance terms include 12-month base salary continuation and accelerated equity vesting on qualifying termination.","Promotion supports late-stage development of mavorixafor and preparations for potential commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-21-018381","json":"https://secwatch.observer/filing/0001628280-21-018381.json","markdown":"https://secwatch.observer/filing/0001628280-21-018381.md","text":"https://secwatch.observer/filing/0001628280-21-018381.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828021018381/0001628280-21-018381-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828021018381/xfor-20210910.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T04:30:51.088244+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"56ee2509e4","claim":"Mary DiBiase was appointed as Chief Operating Officer at X4 Pharmaceuticals, Inc.","evidence_excerpt":"On September 8, 2021, X4 Pharmaceuticals, Inc. (the “Company”) announced the appointment of Mary DiBiase, Ph.D., age 60, as the Company’s Chief Operating Officer, effective as of September 8, 2021 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828021018381/0001628280-21-018381-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}